[go: up one dir, main page]

MX2017012942A - Formulaciones farmaceuticas. - Google Patents

Formulaciones farmaceuticas.

Info

Publication number
MX2017012942A
MX2017012942A MX2017012942A MX2017012942A MX2017012942A MX 2017012942 A MX2017012942 A MX 2017012942A MX 2017012942 A MX2017012942 A MX 2017012942A MX 2017012942 A MX2017012942 A MX 2017012942A MX 2017012942 A MX2017012942 A MX 2017012942A
Authority
MX
Mexico
Prior art keywords
formulations
pharmaceutical formulations
thien
methanesulfonyl
oxo
Prior art date
Application number
MX2017012942A
Other languages
English (en)
Other versions
MX387639B (es
Inventor
Chandra Gupta Ramesh
Deshpande Shailesh
Chaudhari Anita
Dutt Chaitanya
Kesarwani Amit
Patel Manish
Kumar Zambad Shital
Latad Sachin
Kotecha Jignesh
Mishra Vivek
Mathur Anoop
Abraham Jaya
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of MX2017012942A publication Critical patent/MX2017012942A/es
Publication of MX387639B publication Critical patent/MX387639B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere a formulaciones farmacéuticas que comprenden 1-(2-tien-2'-il-2-oxo-etil)-3-(metansulfonil-hidrazina carbonil) piridinio, sus sales farmacéuticamente aceptables, sal-cocristales y cocristales, particularmente cloruro de 1-(2-tien-2'-il-2-oxo-etil)-3-(metansulfonil-hidrazina-carbonil) piridinio. Las formulaciones son adecuadas para la administración oral y también comprenden un potenciador de la permeabilidad o una base adecuada o una mezcla de los mismos. Las formulaciones de esta invención son para tratar enfermedades asociadas con productos finales de glicación avanzada.
MX2017012942A 2015-04-08 2016-04-05 Formulaciones farmacéuticas de compuesto de piridinio y un potenciador de la permeabilidad o una base. MX387639B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1475MU2015 2015-04-08
PCT/IB2016/051920 WO2016162787A1 (en) 2015-04-08 2016-04-05 Pharmaceutical formulations

Publications (2)

Publication Number Publication Date
MX2017012942A true MX2017012942A (es) 2018-01-30
MX387639B MX387639B (es) 2025-03-18

Family

ID=55808800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012942A MX387639B (es) 2015-04-08 2016-04-05 Formulaciones farmacéuticas de compuesto de piridinio y un potenciador de la permeabilidad o una base.

Country Status (31)

Country Link
US (1) US10772879B2 (es)
EP (1) EP3280447B1 (es)
JP (1) JP6736656B2 (es)
KR (1) KR20170134662A (es)
CN (1) CN107530287B (es)
AR (1) AR104185A1 (es)
AU (1) AU2016246124B2 (es)
BR (1) BR112017021669A2 (es)
CA (1) CA2997463A1 (es)
CY (1) CY1121921T1 (es)
DK (1) DK3280447T3 (es)
EA (1) EA037041B1 (es)
ES (1) ES2724629T3 (es)
HR (1) HRP20190783T1 (es)
HU (1) HUE044889T2 (es)
IL (1) IL254794B (es)
LT (1) LT3280447T (es)
MX (1) MX387639B (es)
MY (1) MY182008A (es)
PH (1) PH12017501829A1 (es)
PL (1) PL3280447T3 (es)
PT (1) PT3280447T (es)
RS (1) RS58708B1 (es)
SG (1) SG11201708142XA (es)
SI (1) SI3280447T1 (es)
SM (1) SMT201900264T1 (es)
TR (1) TR201906476T4 (es)
TW (1) TWI713512B (es)
UA (1) UA123051C2 (es)
WO (1) WO2016162787A1 (es)
ZA (1) ZA201707094B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014007972A2 (en) 2012-06-15 2014-01-09 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinphrine
ES2882530T3 (es) 2013-03-22 2021-12-02 Univ Nova Southeastern Partículas finas de epinefrina y métodos para uso de las mismas para el tratamiento de condiciones que responden a la epinefrina
JP7657457B2 (ja) 2018-10-19 2025-04-07 ノバ サウスイースタン ユニバーシティー ｐＨ修飾賦形剤及び浸入促進剤を含む舌下エピネフリン組成物及びそれを使用する方法
US12178814B2 (en) 2019-04-03 2024-12-31 Astellas Pharma Inc. Pharmaceutical composition
KR102330597B1 (ko) * 2020-04-17 2021-11-26 보령제약 주식회사 무정형의 엠파글리플로진을 포함하는 안정성이 향상된 신규 약제학적 제형
KR20220080880A (ko) * 2020-12-08 2022-06-15 주식회사 종근당 엠파글리플로진 공결정을 함유하는 약제학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1154761B1 (en) * 1999-02-22 2008-02-20 Merrion Research I Limited Solid oral dosage form containing an enhancer
AU769940B2 (en) * 1999-10-06 2004-02-12 Torrent Pharmaceuticals Ltd Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
EP1243581B1 (en) 2001-03-21 2005-07-13 Torrent Pharmaceuticals Ltd Pyridinium compounds useful for the treatment of AGE-related diseases
BRPI0708507A2 (pt) 2006-03-03 2011-05-31 Torrent Pharmaceuticals Ltd Novos antagonistas de receptores de dupla ação (dara) para os receptores at1 eta
JP2009023932A (ja) * 2007-07-18 2009-02-05 Tama Tlo Kk Ｎ−メチルピリジニウム化合物を有効成分として含有する抗ウイルス剤、それを含有する、抗ウイルス組成物、食餌及び動物用飼料
US20110034378A1 (en) * 2008-01-25 2011-02-10 Chaitanya Dutt Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc.
CN101574343B (zh) * 2008-05-07 2011-06-01 吉林大学 一种治疗糖尿病的药物组合物
WO2010128528A2 (en) * 2009-05-07 2010-11-11 Torrent Pharmaceuticals Limited Novel heterocyclic compounds
WO2011084618A2 (en) * 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
CN104069066B (zh) * 2013-03-25 2017-04-19 吉林大学 黄癸固体分散体及其在治疗糖尿病及并发症中的应用

Also Published As

Publication number Publication date
TR201906476T4 (tr) 2019-05-21
MX387639B (es) 2025-03-18
EP3280447B1 (en) 2019-02-27
KR20170134662A (ko) 2017-12-06
AU2016246124B2 (en) 2019-11-14
LT3280447T (lt) 2019-05-27
PH12017501829A1 (en) 2018-04-23
PT3280447T (pt) 2019-05-14
TWI713512B (zh) 2020-12-21
RS58708B1 (sr) 2019-06-28
BR112017021669A2 (pt) 2018-07-10
DK3280447T3 (da) 2019-05-13
IL254794A0 (en) 2017-12-31
CY1121921T1 (el) 2020-10-14
US10772879B2 (en) 2020-09-15
US20180110763A1 (en) 2018-04-26
ES2724629T3 (es) 2019-09-12
AR104185A1 (es) 2017-07-05
PL3280447T3 (pl) 2019-07-31
JP2018510916A (ja) 2018-04-19
TW201642858A (zh) 2016-12-16
CN107530287A (zh) 2018-01-02
CN107530287B (zh) 2020-11-10
IL254794B (en) 2021-05-31
ZA201707094B (en) 2021-04-28
SMT201900264T1 (it) 2019-07-11
AU2016246124A1 (en) 2017-11-02
SG11201708142XA (en) 2017-11-29
JP6736656B2 (ja) 2020-08-05
HUE044889T2 (hu) 2019-11-28
CA2997463A1 (en) 2016-10-13
MY182008A (en) 2021-01-18
EP3280447A1 (en) 2018-02-14
WO2016162787A1 (en) 2016-10-13
SI3280447T1 (sl) 2019-06-28
UA123051C2 (uk) 2021-02-10
EA037041B1 (ru) 2021-01-29
HRP20190783T1 (hr) 2019-06-28
EA201792237A1 (ru) 2018-02-28

Similar Documents

Publication Publication Date Title
JOP20200001A1 (ar) كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
IL283134A (en) Alcohol-resistant drug formulations
IL264210A (en) High-strength oral cannabinoid dosage forms
ECSP22018571A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
MX2017012942A (es) Formulaciones farmaceuticas.
DOP2017000306A (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
UA122346C2 (uk) ТЕТРАГІДРО-1H-ПІРИДО[3,4-b]ІНДОЛЬНІ АНТИЕСТРОГЕННІ ЛІКАРСЬКІ ПРЕПАРАТИ
MX387322B (es) Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
MA55015A (fr) Formulations pharmaceutiques
UY36124A (es) Derivados de carboxamida
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
UY36123A (es) Derivados de carboxamida
PL3746441T3 (pl) Związek farmaceutyczny, jego sole, jego preparaty oraz sposoby ich wytwarzania i zastosowania
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
MX373227B (es) Sales farmacéuticamente aceptables de enantiómeros de pirlindol para utilizarse en medicina.
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
MX374540B (es) Desmopresina estabilizada.
CY1123966T1 (el) Διαδικασια για την παρασκευη νατριουχου εποπροστενολης ενισχυμενης σταθεροτητας